Existing studies have demonstrated that CXCL8 can be used as a biomarker of systemic inflammatory response syndrome (SIRS); its up-regulation suggests short-term high mortality (Mikacenic et al., 2017). Here, CXCL8 is linked to systemic inflammatory response syndrome.